Status:
COMPLETED
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Neuralgia, Postherpetic
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.
Eligibility Criteria
Inclusion
- Visual Analogue Scale (VAS) of pain is higher than 40 mm.
- Pain is sustained for more than 3 months after healing of herpes zoster skin rash.
Exclusion
- Malignancy within the past 2 years.
- Patients who have undergone neurolytic or neurosurgical therapy for postherpetic neuralgia.
- Creatinine clearance \</= 30 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation, by omitting any decimal fractions).
- Patients having other severe pain which may impair the self assessment of the pain due to postherpetic neuralgia.
- Skin conditions in the affected dermatome that could alter sensation.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
372 Patients enrolled
Trial Details
Trial ID
NCT00394901
Start Date
September 1 2006
End Date
November 1 2007
Last Update
February 9 2021
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Nagoya, Aichi-ken, Japan
2
Pfizer Investigational Site
Ichikawa, Chiba, Japan
3
Pfizer Investigational Site
Urayasu, Chiba, Japan
4
Pfizer Investigational Site
Kasuga, Fukuoka, Japan